Manas Chandrashekar, John Curran, Ryan Chan
January 23, 2026
Kirkland Advises Platinum Equity on Financing for Acquisition of Inventia Healthcare

1 min
AI-made summary
- Kirkland & Ellis advised Platinum Equity on the debt financing for its acquisition of a controlling stake in Inventia Healthcare Limited’s core Oral Solid Dosage business from India Life Sciences Fund III, NYLIM Jacob Ballas India Fund III, LLC, Mauritius, and affiliates of the founding Shah family, who will retain a minority stake
- Inventia supplies semi-finished and finished OSD formulations to over 100 customers in more than 40 countries
- The Kirkland team was led by Manas Chandrashekar, John Curran, and Ryan Chan.
Kirkland & Ellis advised Platinum Equity on the debt financing for its acquisition of a controlling stake in Mumbai-based generic pharmaceutical business Inventia Healthcare Limited’s core Oral Solid Dosage business (Inventia) from India Life Sciences Fund III (advised by InvAscent), NYLIM Jacob Ballas India Fund III, LLC, Mauritius and affiliates of the company’s founding Shah family. The Shah family is retaining a minority stake in Inventia. Inventia serves as a partner to over 100 customers supplying both semi-finished and finished OSD formulations for both regular and value-added generics. Inventia’s partners include global and leading local pharmaceuticals companies that sell in more than 40 countries across North America, South America, Europe, Southeast Asia, Middle East and Africa. The Kirkland team was led by debt finance partners Manas Chandrashekar and John Curran and associate Ryan Chan.
Article Author
Manas Chandrashekar, John Curran, Ryan Chan
The Sponsor
